Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Market Movers
TipRanks 50 Index
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Private Companies
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans & Pricing
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Advertisement
Advertisement
PHVS
Stock Latest News
Ratings
Pharvaris: Multiple Late‑Stage Catalysts, Differentiated Oral HAE Franchise, and Solid Cash Runway Support Buy Rating and $48 Target
3d ago
PHVS
Premium
Company Announcements
Pharvaris Sets 2026 Roadmap as Deucrictibant Advances Toward NDA Filing and Phase 3 Readouts
3d ago
6K
PHVS
Premium
Market News
3 ‘Strong Buy’ Biotech Stocks to Buy Now, According to Top Analysts
1M ago
IMNM
KYTX
Premium
The Fly
Pharvaris price target raised to $50 from $44 at Oppenheimer
1M ago
KALV
PHVS
Premium
The Fly
Pharvaris price target raised to $39 from $32 at Guggenheim
1M ago
PHVS
Premium
Ratings
Pharvaris’s Deucrictibant: Promising Efficacy Amidst Uncertain Market Prospects
1M ago
PHVS
Premium
The Fly
Pharvaris price target raised to $30 from $27 at BofA
1M ago
PHVS
Premium
The Fly
Pharvaris price target raised to $41 from $37 at Morgan Stanley
1M ago
PHVS
Premium
Ratings
Pharvaris’ Deucrictibant Shows Promising Efficacy and Safety in RAPIDe-3 Study, Analyst Sets Buy Rating with Increased Price Target
1M ago
PHVS
Premium
The Fly
Pharvaris price target raised to $38 from $28 at Leerink
1M ago
PHVS
Premium
The Fly
Midday Fly By: Anthropic starts work on IPO, Marvell reports Q3 beat
1M ago
M
W
Premium
Ratings
Promising Potential of Pharvaris’s Deucrictibant in HAE Treatment Drives Buy Rating
1M ago
PHVS
Premium
Ratings
Pharvaris’s IR Deucrictibant Shows Promising Phase 3 Results for HAE Treatment
1M ago
PHVS
Premium
The Fly
Morning Movers: Macy’s dips following third quarter earnings report
1M ago
M
AEO
Premium
Company Announcements
Pharvaris Announces Positive Results from RAPIDe-3 Study for HAE Treatment
1M ago
6K
PHVS
Premium
The Fly
Pharvaris’ deucrictibant meets primary endpoint in HAE attack trial
1M ago
PHVS
Premium
Company Announcements
Pharvaris Reports Q3 2025 Financial Results and Updates
2M ago
PHVS
Premium
Ratings
Pharvaris: Strong Buy Rating Backed by Promising Clinical Trials and Robust Financial Health
2M ago
PHVS
Premium
The Fly
Pharvaris price target raised to $37 from $34 at Morgan Stanley
2M ago
PHVS
Premium
Company Announcements
Pharvaris Reports Q3 2025 Financial Results and Business Progress
2M ago
6K
PHVS
Premium
Ratings
Promising Phase 3 Trial Data Drives Buy Rating for Deucrictibant
3M ago
PHVS
Premium
The Fly
Six new option listings on October 24th
3M ago
SEV
DFDV
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >
You need to enable JavaScript to run this app.
